Afatinib (BIBW 2992)

From HemOnc.org - A Hematology Oncology Wiki

Jump to: navigation, search

Also known as Tomtovok. In clinical trials

General information

Class/mechanism: Irreversible tyrosine kinase inhibitor of members of the erbB family, such as EGFR (epidermal growth factor receptor) and HER2 (human epidermal growth factor receptor 2)[1]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.

Patient drug information

No information available.

References

  1. Press release: Boehringer Ingelheim broadens its breast cancer clinical trial program for the investigational compound afatinib
Personal tools
Namespaces
Variants
Actions
Index
References
Stay in touch
Share This Page
Toolbox